367 related articles for article (PubMed ID: 25417702)
1. Functional interplay between MDM2, p63/p73 and mutant p53.
Stindt MH; Muller PA; Ludwig RL; Kehrloesser S; Dötsch V; Vousden KH
Oncogene; 2015 Aug; 34(33):4300-10. PubMed ID: 25417702
[TBL] [Abstract][Full Text] [Related]
2. P53 family: at the crossroads in cancer therapy.
Alsafadi S; Tourpin S; André F; Vassal G; Ahomadegbe JC
Curr Med Chem; 2009; 16(32):4328-44. PubMed ID: 19754415
[TBL] [Abstract][Full Text] [Related]
3. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain.
Gaiddon C; Lokshin M; Ahn J; Zhang T; Prives C
Mol Cell Biol; 2001 Mar; 21(5):1874-87. PubMed ID: 11238924
[TBL] [Abstract][Full Text] [Related]
4. Interaction of regulators Mdm2 and Mdmx with transcription factors p53, p63 and p73.
Zdzalik M; Pustelny K; Kedracka-Krok S; Huben K; Pecak A; Wladyka B; Jankowski S; Dubin A; Potempa J; Dubin G
Cell Cycle; 2010 Nov; 9(22):4584-91. PubMed ID: 21088494
[TBL] [Abstract][Full Text] [Related]
5. TAp73 alpha increases p53 tumor suppressor activity in thyroid cancer cells via the inhibition of Mdm2-mediated degradation.
Malaguarnera R; Vella V; Pandini G; Sanfilippo M; Pezzino V; Vigneri R; Frasca F
Mol Cancer Res; 2008 Jan; 6(1):64-77. PubMed ID: 18234963
[TBL] [Abstract][Full Text] [Related]
6. MDM2 and MDMX can interact differently with ARF and members of the p53 family.
Wang X; Arooz T; Siu WY; Chiu CH; Lau A; Yamashita K; Poon RY
FEBS Lett; 2001 Feb; 490(3):202-8. PubMed ID: 11223036
[TBL] [Abstract][Full Text] [Related]
7. MDM2, MDMX, and p73 regulate cell-cycle progression in the absence of wild-type p53.
Klein AM; Biderman L; Tong D; Alaghebandan B; Plumber SA; Mueller HS; van Vlimmeren A; Katz C; Prives C
Proc Natl Acad Sci U S A; 2021 Nov; 118(44):. PubMed ID: 34716260
[TBL] [Abstract][Full Text] [Related]
8. Targeting of p53 and its homolog p73 by protoporphyrin IX.
Sznarkowska A; Maleńczyk K; Kadziński L; Bielawski KP; Banecki B; Zawacka-Pankau J
FEBS Lett; 2011 Jan; 585(1):255-60. PubMed ID: 21146529
[TBL] [Abstract][Full Text] [Related]
9. Intrinsic aggregation propensity of the p63 and p73 TI domains correlates with p53R175H interaction and suggests further significance of aggregation events in the p53 family.
Kehrloesser S; Osterburg C; Tuppi M; Schäfer B; Vousden KH; Dötsch V
Cell Death Differ; 2016 Dec; 23(12):1952-1960. PubMed ID: 27447112
[TBL] [Abstract][Full Text] [Related]
10. TopBP1 mediates mutant p53 gain of function through NF-Y and p63/p73.
Liu K; Ling S; Lin WC
Mol Cell Biol; 2011 Nov; 31(22):4464-81. PubMed ID: 21930790
[TBL] [Abstract][Full Text] [Related]
11. P53 and p73 differ in their ability to inhibit glucocorticoid receptor (GR) transcriptional activity.
Zhang L; Nie L; Maki CG
Mol Cancer; 2006 Dec; 5():68. PubMed ID: 17150106
[TBL] [Abstract][Full Text] [Related]
12. Studying p53 family proteins in yeast: induction of autophagic cell death and modulation by interactors and small molecules.
Leão M; Gomes S; Bessa C; Soares J; Raimundo L; Monti P; Fronza G; Pereira C; Saraiva L
Exp Cell Res; 2015 Jan; 330(1):164-77. PubMed ID: 25265062
[TBL] [Abstract][Full Text] [Related]
13. Evolution of the p53-MDM2 pathway.
Åberg E; Saccoccia F; Grabherr M; Ore WYJ; Jemth P; Hultqvist G
BMC Evol Biol; 2017 Aug; 17(1):177. PubMed ID: 28774266
[TBL] [Abstract][Full Text] [Related]
14. Evolution of functions within the p53/p63/p73 family.
De Laurenzi V; Melino G
Ann N Y Acad Sci; 2000; 926():90-100. PubMed ID: 11193045
[TBL] [Abstract][Full Text] [Related]
15. p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53.
Davison TS; Vagner C; Kaghad M; Ayed A; Caput D; Arrowsmith CH
J Biol Chem; 1999 Jun; 274(26):18709-14. PubMed ID: 10373484
[TBL] [Abstract][Full Text] [Related]
16. p73 expression modulates p63 and Mdm2 protein presence in complex with p53 family-specific DNA target sequence in squamous cell carcinogenesis.
Johnson J; Lagowski J; Lawson S; Liu Y; Kulesz-Martin M
Oncogene; 2008 Apr; 27(19):2780-7. PubMed ID: 18026135
[TBL] [Abstract][Full Text] [Related]
17. p73 and p63 sustain cellular growth by transcriptional activation of cell cycle progression genes.
Lefkimmiatis K; Caratozzolo MF; Merlo P; D'Erchia AM; Navarro B; Levrero M; Sbisa' E; Tullo A
Cancer Res; 2009 Nov; 69(22):8563-71. PubMed ID: 19861536
[TBL] [Abstract][Full Text] [Related]
18. How many mutant p53 molecules are needed to inactivate a tetramer?
Chan WM; Siu WY; Lau A; Poon RY
Mol Cell Biol; 2004 Apr; 24(8):3536-51. PubMed ID: 15060172
[TBL] [Abstract][Full Text] [Related]
19. Structural convergence of unstructured p53 family transactivation domains in MDM2 recognition.
Shin JS; Ha JH; Lee DH; Ryu KS; Bae KH; Park BC; Park SG; Yi GS; Chi SW
Cell Cycle; 2015; 14(4):533-43. PubMed ID: 25591003
[TBL] [Abstract][Full Text] [Related]
20. The p53 gene family.
Kaelin WG
Oncogene; 1999 Dec; 18(53):7701-5. PubMed ID: 10618710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
